Agios Pharmaceuticals | AGIO - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 4.73B 1.08B 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amgen USD 3.83B 130M 2026-03
Arrowhead Research USD -141.26M 182.07M 2026-03
Astellas Pharma JPY 48.57B 85.97B 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Bayer EUR 3.53B 2.42B 2026-03
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Exelixis USD 251.34M 15.43M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.29B 856M 2026-03
Incyte USD 324.17M 59.7M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Merck USD -1.88B 8.12B 2026-03
Moderna USD -1.39B 531M 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Novartis USD 4.24B 171M 2026-03
Novartis USD 4.06B 521M 2025-12
Pfizer USD 4.99B 340M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03